Alvaro Borges

Chief Medical Officer

Statens Serum Institut, Denmark

Email: albs@ssi.dk

VALIDATE Role:

Network Investigator

Research Keywords:

Clinical Research, Clinical Trials, Infectious Diseases, Vaccines, Epidemiology, Tropical Medicine and HIV.

Biography:

Alvaro Borges is a physician-scientist educated in Brazil, the United Kingdom and Denmark. He has an MSc degree in Tropical and Infectious Diseases by the Liverpool School of Tropical Medicine (2011) and a PhD in Immunology and Infectious Diseases by the University of Copenhagen (2015). He has joined the"Center for Vaccine Research (CVR) at Statens Serum lnstitut in Denmark as Chief Medical Officer to work on clinical trials testing new candidate vaccines in humans.

Alvaro has been actively involved in 1) design and coordination of clinical trials and research projects primarily within vaccines, 2) studies of pathogen mechanisms and natural immunity/ vaccine immunity in human cohorts, 3) clinical data interpretation, preparation of scientific manuscripts and presentations at international meetings and 4) fund raising for clinical trials. Alvaro has more than 12 years' experience working as a medical officer of multinational trials involving participants with infectious diseases. He has considerable expertise in clinical research, clinical trials, infectious diseases, vaccines, epidemiology, tropical medicine and HIV.

Related Websites:

Statens Serum Institut

Key Publications:

Borges, Álvaro H.; Silverberg, Michael J.; Wentworth, Deborah; Grulich, Andrew E.; Fätkenheuer, Gerd; Mitsuyasu, Ronald; Tambussi, Giuseppe; Sabin, Caroline A.; Neaton, James D.; Lundgren, Jens D.; for the INSIGHT SMART, ESPRIT, SILCAAT Study Groups. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 27(9):1433-1441, June 1, 2013
Álvaro H. Borges, Andreas Lundh, Britta Tendal, John A. Bartlett, Nathan Clumeck, Dominique Costagliola, Eric S. Daar, Patrícia Echeverría, Magnus Gisslén, Tania B. Huedo-Medina, Michael D. Hughes, Katherine Huppler Hullsiek, Paul Khabo, Stephanus Komati, Princy Kumar, Shahin Lockman, Rodger D. MacArthur, Franco Maggiolo, Alberto Matteelli, Jose M. Miro, Shinichi Oka, Kathy Petoumenos, Rebekah L. Puls, Sharon A. Riddler, Paul E. Sax, Juan Sierra-Madero, Carlo Torti and Jens D. Lundgren. Non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based regimens for initial treatment of HIV infection: a systematic review and meta-analysis of randomised trials. Clin Infect Dis. 2016 Jul 15;63(2):268-80.
Borges ÁH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugyenyi P, Domingo P, Hoffmann C, Read TR, Pujari S, Meulbroek M, Johnson M, Wilkin T, Mitsuyasu R; INSIGHT START Study Group. Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. Clin Infect Dis. 2016 Dec 15;63(12):1668-1676.
Borges ÁH, Follmann F, Dietrich J. Chlamydia trachomatis vaccine development - a view on the current challenges and how to move forward. Expert Rev Vaccines. 2022 Sep 5:1-13. doi: 10.1080/14760584.2022.2117694. Online ahead of print. PMID: 36004386
Knudsen AD, Eskelund CW, Benfield T, Zhao Y, Gelpi M, Køber L, Trøseid M, Kofoed KF, Ostrowski SR, Reilly C, Borges ÁH*, Grønbæk K*, Nielsen SD*. Clonal hematopoiesis of indeterminate potential in Persons living with HIV. AIDS. 2023 Nov 16. doi: 10.1097/QAD.0000000000003788. Online ahead of print.PMID: 37976039. *shared senior co-authorship
Tait D, Diacon A, Borges ÁH*, van Brakel E, Hokey D, Rutkowski KT, Hunt DJ, Russell M, Andersen PL, Kromann I, Ruhwald M, Churchyard G, Dawson R. Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial. J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093/infdis/jiae170. Epub ahead of print. PMID: 38557639. *corresponding author
Katrina M Pollock*, Álvaro H Borges*, Hannah M Cheeseman, Ida Rosenkrands, Kirstine L Schmidt, Rie E Søndergaard, Suzanne Day, Abbey Evans, Leon R McFarlane, Jennifer Joypooranachandran, Fahimah Amini, Per Skallerup, Rebecca B Dohn, Charlotte G Jensen, Anja W Olsen, Peter Bang, Tom Cole, Joanna Schronce, Nana-Marie Lemm, Max P Kristiansen, Peter L Andersen, Jes Dietrich, Robin J Shattock, Frank Follmann. An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial. The Lancet Infectious Diseases 2024 (in press). * shared first co-authorship.